FDA considers expanding indication for Cymbalta; side effects SJS, TEN
A Food and Drug Administration (FDA) advisory committee has narrowly voted to recommend that the indication for Eli Lilly’s antidepressant Cymbalta (duloxetine) be expanded to include use as a treatment for chronic musculoskeletal pain. The Anesthetic and Life Support Drugs Advisory Committee also voted that the benefits were minimal but outweighed the risks, which includes a black box warning of suicidality in children, adolescents and young adults; a potential for liver damage; and a risk of developing the rare skin disease Stevens Johnson Syndrome (SJS) and its more serious form, toxic epidermal necrolysis (TEN).
Famotidine, the heartburn drug most known by the brand name Pepcid, is yet another drug that has been linked to a deadly skin reaction known as 
Health Canada has ordered Pfizer Canada to issue stronger warnings about its smoking cessation medication Champix, also known as